Table 4.
Clinicopathologic features associated with survival after brain metastasis
| Clinicopathologic feature | Univariable analysis |
Multivariable analysis |
||
|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | |
| Age at diagnosis of brain metastasis | 1.02 (1.00-1.04) | .036 | 1.00 (0.98-1.02) | >.9 |
| Karnofsky performance status | 0.97 (0.95-0.98) | <.001 | 0.98 (0.96-0.99) | .008 |
| Number of brain metastases | 1.04 (1.02-1.07) | .002 | 1.02 (0.99-1.05) | .2 |
| Location of brain metastasis (vs both supratentorial and infratentorial) | ||||
| Supratentorial | 0.71 (0.48-1.05) | .086 | — | — |
| Infratentorial | 0.69 (0.35-1.35) | .3 | — | — |
| Leptomeningeal disease only | 1.74 (0.88-3.41) | .11 | — | — |
| Size of largest metastasis | 0.93 (0.81-1.08) | .3 | — | — |
| Extracranial metastasis present | 1.73 (1.24-2.41) | .001 | 1.52 (1.00-2.32) | .049 |
| Craniotomy | 0.48 (0.33-0.70) | <.001 | 0.75 (0.45-1.27) | .3 |
| Stereotactic radiosurgery | 0.41 (0.29-0.58) | <.001 | 0.35 (0.21-0.57) | <.001 |
| Whole-brain radiation | 1.58 (1.11-2.26) | .012 | 1.12 (0.67-1.85) | .7 |
| Targeted therapy | 0.63 (0.43-0.93) | .019 | 0.42 (0.26-0.70) | <.001 |
| Immunotherapy | 1.11 (0.76-1.61) | .6 | — | — |
| Chemotherapy | 1.03 (0.73-1.45) | .9 | — | — |
Bold type indicates statistical significance. HR, Hazard ratio; CI, confidence interval.